Targeting the urokinase plasminogen activator pathway inhibits pancreatic cancer progression

被引：0
|
作者：
Hosen, S. M. Z. [1 ,2 ]
Haar, J. [1 ,2 ]
Xu, Z. [1 ,2 ]
Perera, C. [1 ,2 ]
Mekapogu, A. R. [1 ,2 ]
Pang, T. C. Y. [1 ,2 ]
Pothula, S. [1 ,2 ]
Goldstein, D. [1 ]
Pirola, R. [1 ]
Wilson, J. [1 ]
Buckley, B. J. [3 ,4 ,5 ]
Ranson, M. [3 ,4 ,5 ]
Apte, M. [1 ,2 ]
机构：
[1] Univ New South Wales, Pancreat Res Grp, South Western Sydney Clin Sch, Fac Med, Sydney, NSW, Australia
[2] Ingham Inst Appl Med Res, Sydney, NSW, Australia
[3] Univ Wollongong, Mol Horizons, Fac Sci Med & Hlth, Wollongong, NSW, Australia
[4] Univ Wollongong, Sch Chem & Mol Biosci, Fac Sci Med & Hlth, Wollongong, NSW, Australia
[5] Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
219
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [31] Amiloride Analogues as Inhibitors of Human Urokinase Plasminogen Activator and Anti-Pancreatic Cancer Agents
    Xu, Z.
    Buckley, B. J.
    Pothula, S.
    Pang, T.
    Goldstein, D.
    Pirola, R. C.
    Wilson, J. S.
    Kelso, M. J.
    Ranson, M.
    Apte, M. V.
    PANCREAS, 2018, 47 (10) : 1434 - 1434
  • [32] Downregulation of urokinase-type plasminogen activator inhibitor (PAI-1) in pancreatic cancer
    Metzger, R.
    Warnecke-Eberz, U.
    Prenzel, K. L.
    Baldus, S. E.
    Brabender, J.
    Vallboehmer, D.
    Hoelscher, A. H.
    Schneider, P. M.
    EJC SUPPLEMENTS, 2006, 4 (06): : 27 - 27
  • [33] APROTININ INHIBITS UROKINASE BUT NOT TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    LOTTENBERG, R
    SJAKSHIE, N
    FAZLEABAS, AT
    ROBERTS, RM
    THROMBOSIS RESEARCH, 1988, 49 (06) : 549 - 556
  • [34] Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling
    Popa, Nicoleta L.
    Wergedal, Jon E.
    Lau, K. -H. William
    Mohan, Subburaman
    Rundle, Charles H.
    JOURNAL OF BONE AND MINERAL METABOLISM, 2014, 32 (02) : 124 - 135
  • [35] Circulating levels of urokinase-type plasminogen activator (uPA) in breast and pancreatic cancer patients
    Hamer, PJ
    Marx, JH
    Leitzel, K
    Ali, S
    Clarke, L
    Demers, L
    Harvey, HA
    Linnartz, R
    Lipton, A
    Mietlowski, W
    Carney, WP
    CLINICAL CHEMISTRY, 2005, 51 : A53 - A54
  • [36] Urokinase plasminogen activator system - A multifunction role in tumor progression and metastasis
    Choong, PFM
    Nadesapillai, APW
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2003, (415) : S46 - S58
  • [37] The Role of the Urokinase-Type Plasminogen Activator System In Tumor Progression
    E. V. Kugaevskaya
    T. A. Gureeva
    O. S. Timoshenko
    N. I. Solovyeva
    Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry, 2019, 13 : 97 - 112
  • [38] AMILORIDE SELECTIVELY INHIBITS THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    VASSALLI, JD
    BELIN, D
    FEBS LETTERS, 1987, 214 (01) : 187 - 191
  • [39] The Role of the Urokinase-Type Plasminogen Activator System In Tumor Progression
    Kugaevskaya, E., V
    Gureeva, T. A.
    Timoshenko, O. S.
    Solovyeva, N., I
    BIOCHEMISTRY MOSCOW-SUPPLEMENT SERIES B-BIOMEDICAL CHEMISTRY, 2019, 13 (02) : 97 - 112
  • [40] Macrophages overexpressing urokinase plasminogen activator are sufficient to promote atherosclerosis progression
    Krishnan, R
    Kremen, M
    Slezicki, K
    Shi, HK
    Dichek, H
    Moriwaki, H
    Dichek, D
    CIRCULATION, 2005, 112 (17) : U127 - U127
12345